News

US FDA extends review of GSK's blood cancer drug

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment ...

GSK says US FDA extends review period for Blenrep BLA until October

(Alliance News) - GSK PLC on Wednesday said the US Food & Drug Administration has extended the review period for Blenrep combinations in relapsed/refractory multiple myeloma after an advisory ...
Fierce Pharma7h

FDA delays Blenrep decision, putting GSK's multiple myeloma comeback dreams on ice

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...